Table 1.
Clinical characteristics of patients in the ICI cohort from 120 patients with metastatic cancer receiving ICI therapy
| Features | Training cohort | Validation cohort | P-value |
|---|---|---|---|
| (N = 91) | (N = 29) | ||
| Sex | |||
| Male | 61.0 (67.0%) | 20.0 (69.0%) | 1 |
| Female | 30.0 (33.0%) | 9.00 (31.0%) | |
| Age | |||
| ≤ 60 | 38.0 (41.8%) | 15.0 (51.7%) | 0.468 |
| > 60 | 53.0 (58.2%) | 14.0 (48.3%) | |
| Brain metastases | |||
| No | 83.0 (91.2%) | 26.0 (89.7%) | 1 |
| Yes | 8.00 (8.8%) | 3.00 (10.3%) | |
| PD-L1 | |||
| < 1% | 16.0 (17.6%) | 2.00 (6.9%) | 0.389 |
| 1%–49% | 9.00 (9.9%) | 0 (0%) | |
| 50%–100% | 7.00 (7.7%) | 0 (0%) | |
| Missing | 59.0 (64.8%) | 27.0 (93.1%) | |
| Response | |||
| PR | 23.0 (25.3%) | 9.00 (31.0%) | 0.823 |
| SD | 50.0 (54.9%) | 15.0 (51.7%) | |
| PD | 18.0 (19.8%) | 5.00 (17.2%) | |
| Clinical status | |||
| DCB | 52.0 (57.1%) | 15.0 (51.7%) | 0.407 |
| NDB_LS | 10.0 (11.0%) | 6.00 (20.7%) | |
| NDB_SS | 29.0 (31.9%) | 8.00 (27.6%) | |
| Previous lines of treatment | |||
| 1 | 34.0 (37.4%) | 13.0 (44.8%) | 0.591 |
| 2 | 38.0 (41.8%) | 8.00 (27.6%) | |
| 3 | 14.0 (15.4%) | 6.00 (20.7%) | |
| > 3 | 5.00 (5.5%) | 2.00 (6.9%) | |
| PD-1 inhibitor type | |||
| Camrelizumab | 26.0 (28.6%) | 4.00 (13.8%) | 0.288 |
| Nivolumab | 6.00 (6.6%) | 3.00 (10.3%) | |
| Others | 10.0 (11.0%) | 1.00 (3.4%) | |
| Pembrolizumab | 14.0 (15.4%) | 6.00 (20.7%) | |
| Sintilimab | 35.0 (38.5%) | 15.0 (51.7%) | |
DCB durable clinical outcomes, NDB no durable benefit, NDB_LS long-term survival with no durable clinical benefit, NDB_SS short-term survival with no durable clinical benefit